Filing Flows › Charles River Laboratories International (CRL) › Q2 2026
Charles River Laboratories International (CRL) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 5, 2026
Charles River Laboratories International (CRL) reported revenue of $1.0B for the second quarter 2026 (Q2 2026), -3% from a year earlier and +0.8% from the quarter before. Operating margin was 11.9%, net loss $760K (0.1% of revenue).
Charles River Laboratories International, Q2 2026: revenue $1.0B (-3% year over year), operating margin 11.9%, net loss $760K, operating cash flow $180M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.0B | +0.8% | -3% |
| Operating profit | $120M | 0% | +20% |
| Net earnings | −$760K | — | -101% |
| Operating cash flow | $180M | +338% | -12% |
| Free cash flow | $149M | — | -12% |
What changed
Revenue was $1.0B in Q2 2026, down 3% year over year and up 1% from the previous quarter. DSA was the largest line at 60% of revenue. Manufacturing lost $0.01B year over year (down 6%), 45% of the total change.
Operating profit was $0.12B, a 11.9% margin (up 2.2 points year over year). Total costs fell 5% while revenue fell 3%. The fastest-growing cost line was SG&A (+19%). The quarter ended with a net loss of $760K, narrower than the previous quarter's $0.01B loss. Net interest and other expense of $0.07B was the main reason.
Operating cash flow was $0.18B (down 12% year over year). Non-cash charges added back $0.07B of depreciation and amortization and $0.02B of share-based compensation. Working capital and other items added $0.09B. Capital expenditures of $0.03B left free cash flow of $0.15B.
Questions
What was Charles River Laboratories International's revenue in the second quarter 2026?
Charles River Laboratories International (CRL) reported revenue of $1.0B for the second quarter 2026 (Q2 2026), -3% from a year earlier and +0.8% from the quarter before.
Was Charles River Laboratories International profitable in the second quarter 2026?
Operating profit was $120M (11.9% of revenue) and net loss $760K.
Source: Charles River Laboratories International 10-Q on SEC EDGAR.